Invictus MD closes acquisition of shares in ACMPR Licensed Producer AB Laboratories Inc.

Posted on Categories: Investor Relations

VANCOUVER, BC, December 29, 2016 – INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (CSE: IMH; OTC: IVITF; FRA: 8IS) is pleased to announce that it has closed the acquisition of 33.33% of the shares of AB Laboratories Inc. and the initial acquisition of shares of AB Ventures Inc., as previously announced on December 23, 2016.

Dan Kriznic, CEO of Invictus MD, commented, “This investment in AB Laboratories Inc. and AB Ventures Inc. solidifies Invictus MD as a major player on the forefront of the cannabis industry.”

AB Laboratories Inc. is licensed for cultivation under the ACMPR and maintains a 16,000 square foot facility located in Hamilton, Ontario. The Company paid CAD$5,000,000 and issued 2.4 million common shares to the vendor at closing, with a further CAD$2,000,000 in cash due in 90 days.

Read more “Invictus MD closes acquisition of shares in ACMPR Licensed Producer AB Laboratories Inc.”

Invictus MD closes acquisition of ACMPR Licensed Producer AB Laboratories Inc.

Posted on Categories: Investor Relations

VANCOUVER, BC, December 23, 2016 – INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (CSE: IMH; OTC: IVITF; FRA: 8IS) is pleased to announce that it has signed the definitive agreement to acquire 33.33% of AB Laboratories Inc. (“AB Labs”), a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”), and up to 33.33% of AB Ventures Inc. (“AB Ventures”), a newly incorporated company formed to develop a second licensed expansion facility.

Under the terms of the agreement Invictus MD will acquire 33.33% of AB Labs, for consideration of CAD$5,000,000 in cash and 2.4 million common shares of Invictus MD on closing and CAD$2,000,000 in cash 90 days after closing. AB Labs is licensed for cultivation under the ACMPR and maintains a 16,000 square foot facility located in Hamilton, Ontario. Invictus MD will have the right of first refusal to arrange any initial public offering, reverse take-over or other going public transaction of AB Labs or AB Ventures following closing. Closing is expected to take place by December 29, 2016.

Read more “Invictus MD closes acquisition of ACMPR Licensed Producer AB Laboratories Inc.”

Invictus MD hires top tier cannabis consultants and Chief Science Officer for North America wide conquest

Posted on Categories: Investor Relations

Vancouver, BC, December 12, 2016 – INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (CSE: IMH; OTC: IVITF; FRA: 8IS) is pleased to announce it has entered into a consulting agreement with Cannera Consultants (“Cannera”) and has enlisted Phillip Hague to undertake the role of Chief Science Officer and Head of Horticulture.

Cannera, a division of the GreenTec Bio-Pharmaceuticals Group has entered into an agreement with Invictus MD to oversee all Canadian assets and acquisitions within the Access to Cannabis for Medical Purposes Regulations (“ACMPR”), and provide assistance with certain U.S. acquisitions. Cannera, which was the intermediary party in bridging Invictus MD with AB Laboratories Inc, has played an integral role in negotiating and executing the Binding Letter of Intent for this Licensed Producer, signed by both parties on November 23rd, 2016. Cannera’s vast rolodex and expertise in the industry will play a pivotal role in Invictus MD’s aggressive North America wide conquest.

Read more “Invictus MD hires top tier cannabis consultants and Chief Science Officer for North America wide conquest”

Invictus MD announces binding Letter of Intent to acquire 20% Washington i502 Cultivation & Processing License

Posted on Categories: Investor Relations

Vancouver, BC, December 7, 2016 – INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (CSE: IMH; OTC: IVITF; FRA: 8IS) is pleased to announce it has entered into a binding Letter of Intent to acquire a Tier 2 State of Washington Cultivation and Processing License (”The Operation”).

Invictus MD will pay $1,000,000 USD cash by way of a convertible debenture to Cannera Equipment Leasing (“CEL”). CEL has committed up to $1,000,000 USD by way of equipment financing and tenant upgrades to the Licensed facility which is currently in final stages of construction, and will have the capacity to produce 2,500kg annually.

Read more “Invictus MD announces binding Letter of Intent to acquire 20% Washington i502 Cultivation & Processing License”